HK1090571A1 - Methods for preventing mitochondrial permeability transition - Google Patents

Methods for preventing mitochondrial permeability transition

Info

Publication number
HK1090571A1
HK1090571A1 HK06112161.2A HK06112161A HK1090571A1 HK 1090571 A1 HK1090571 A1 HK 1090571A1 HK 06112161 A HK06112161 A HK 06112161A HK 1090571 A1 HK1090571 A1 HK 1090571A1
Authority
HK
Hong Kong
Prior art keywords
methods
permeability transition
mitochondrial permeability
preventing mitochondrial
preventing
Prior art date
Application number
HK06112161.2A
Other languages
English (en)
Inventor
Hazel H Szeto
Kesheng Zhao
Original Assignee
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Res Foundation Inc filed Critical Cornell Res Foundation Inc
Priority to HK09110947.4A priority Critical patent/HK1131995A1/xx
Publication of HK1090571A1 publication Critical patent/HK1090571A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
HK06112161.2A 2003-02-04 2006-11-03 Methods for preventing mitochondrial permeability transition HK1090571A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
HK09110947.4A HK1131995A1 (en) 2003-02-04 2006-11-03 Methods for preventing mitochondrial permeability transition

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44477703P 2003-02-04 2003-02-04
US53569004P 2004-01-08 2004-01-08
PCT/US2004/003193 WO2004070054A2 (en) 2003-02-04 2004-02-03 Methods for preventing mitochondrial permeability transition

Publications (1)

Publication Number Publication Date
HK1090571A1 true HK1090571A1 (en) 2006-12-29

Family

ID=32853391

Family Applications (6)

Application Number Title Priority Date Filing Date
HK06112161.2A HK1090571A1 (en) 2003-02-04 2006-11-03 Methods for preventing mitochondrial permeability transition
HK09110947.4A HK1131995A1 (en) 2003-02-04 2006-11-03 Methods for preventing mitochondrial permeability transition
HK13105866.5A HK1178794A1 (en) 2003-02-04 2013-05-17 Methods for preventing mitochondrial permeability transition
HK14104163.7A HK1190930A1 (en) 2003-02-04 2014-04-30 Uses of aromatic-cationic peptide
HK15105970.6A HK1204999A1 (en) 2003-02-04 2015-06-23 Methods for preventing mitochondrial permeability transition
HK15110675.4A HK1209652A1 (en) 2003-02-04 2015-10-28 Uses of aromatic-cationic peptide

Family Applications After (5)

Application Number Title Priority Date Filing Date
HK09110947.4A HK1131995A1 (en) 2003-02-04 2006-11-03 Methods for preventing mitochondrial permeability transition
HK13105866.5A HK1178794A1 (en) 2003-02-04 2013-05-17 Methods for preventing mitochondrial permeability transition
HK14104163.7A HK1190930A1 (en) 2003-02-04 2014-04-30 Uses of aromatic-cationic peptide
HK15105970.6A HK1204999A1 (en) 2003-02-04 2015-06-23 Methods for preventing mitochondrial permeability transition
HK15110675.4A HK1209652A1 (en) 2003-02-04 2015-10-28 Uses of aromatic-cationic peptide

Country Status (14)

Country Link
US (8) US7576061B2 (xx)
EP (9) EP1599216B9 (xx)
JP (7) JP4838114B2 (xx)
CN (3) CN102784383B (xx)
AU (1) AU2004209663B2 (xx)
CA (1) CA2515080C (xx)
CY (2) CY1114959T1 (xx)
DK (3) DK2656854T3 (xx)
ES (3) ES2436011T3 (xx)
HK (6) HK1090571A1 (xx)
HU (1) HUE027110T2 (xx)
PT (2) PT1599216E (xx)
SI (1) SI2656854T1 (xx)
WO (1) WO2004070054A2 (xx)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2515080C (en) 2003-02-04 2012-04-10 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
DK2604286T3 (en) 2003-05-01 2014-12-08 Cornell Res Foundation Inc Method and carrier complex for delivering molecules to cells
US7550439B2 (en) 2004-01-23 2009-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
AU2014203126B2 (en) * 2005-09-16 2016-03-10 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
EP1931369B1 (en) 2005-09-16 2016-08-17 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing CD36 expression
EP3272353A1 (en) 2008-02-07 2018-01-24 Cornell University Methods for preventing or treating insulin resistance
WO2009108695A2 (en) 2008-02-26 2009-09-03 Cornell University Methods for prevention and treatment of acute renal injury
DE102008061044A1 (de) * 2008-12-11 2010-06-17 Henkel Ag & Co. Kgaa Zusammensetzung mit antioxidativ wirksamen Peptiden
WO2010120431A2 (en) * 2009-03-20 2010-10-21 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods for the prevention and treatment of burn injuries and secondary complications
CN102647994A (zh) * 2009-08-12 2012-08-22 康奈尔大学 预防或治疗代谢综合症的方法
EP3124036A1 (en) * 2009-08-24 2017-02-01 Stealth Peptides International, Inc. Methods and compositions for preventing or treating opthalmic conditions
CN103845724A (zh) * 2009-10-05 2014-06-11 康奈尔大学 预防或治疗心力衰竭的方法
EP3266462A1 (en) * 2009-12-31 2018-01-10 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
EP3269380A1 (en) * 2009-12-31 2018-01-17 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
CA2787331A1 (en) * 2010-01-25 2011-07-28 Hazel H. Szeto Aromatic-cationic peptides and uses of same
CN104922653A (zh) * 2010-02-26 2015-09-23 佛罗里达大学研究基金会有限公司 治疗或预防哺乳动物对象中骨骼肌衰弱的方法
EP3210615A1 (en) 2010-03-15 2017-08-30 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
US20110245182A1 (en) 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
US20110245183A1 (en) 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
EP3290433A1 (en) * 2010-05-03 2018-03-07 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
US20160176930A1 (en) 2010-07-09 2016-06-23 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
JP6319738B2 (ja) * 2010-07-09 2018-05-09 ステルス ペプチドズ インターナショナル インコーポレイテッド 虚血／再灌流障害に続くノーリフローの予防又は処置方法
WO2014137496A1 (en) * 2013-03-08 2014-09-12 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
US20120083452A1 (en) * 2010-09-30 2012-04-05 Perricone Nicholas V Topical Anesthetic Uses of Szeto-Schiller Peptides
EP3108975A1 (en) * 2011-03-24 2016-12-28 Cornell University Aromatic-cationic peptides and uses of same
EP2758411A2 (en) 2011-09-19 2014-07-30 Gencia Corporation Modified creatine compounds
EP2760460B1 (en) 2011-09-29 2019-11-20 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same
CN107261380A (zh) * 2011-10-17 2017-10-20 康奈尔大学 芳香族阳离子肽及其用途
AU2012347931A1 (en) * 2011-12-09 2014-07-03 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
DK2830644T3 (en) * 2012-03-30 2017-02-27 Stealth Peptides Int Inc Methods and Preparations for the Prevention and Treatment of Neuropathy
CN110090304A (zh) * 2012-08-02 2019-08-06 康德生物医疗技术公司 用于治疗动脉粥样硬化的方法
EP2908839B1 (en) * 2012-10-22 2019-08-21 Stealth Peptides International, Inc. Methods for reducing risks associated with heart failure and factors associated therewith
CN116440247A (zh) 2013-03-01 2023-07-18 康德生物医疗有限公司 治疗线粒体疾病的方法
ES2750258T3 (es) 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Métodos y composiciones para la prevención o tratamiento del síndrome de Barth
EP2989120A4 (en) 2013-04-25 2017-04-19 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof
US10047395B2 (en) 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
WO2015017781A1 (en) * 2013-08-01 2015-02-05 Stealth Peptides International, Inc. Methods and compositions for preventing or treating leber's hereditary optic neuropathy
WO2015017861A1 (en) 2013-08-02 2015-02-05 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment of friedreich's ataxia
JP6434523B2 (ja) * 2013-09-30 2018-12-05 コーネル ユニヴァーシティー カルジオリピン標的化ペプチドはベータアミロイドオリゴマー毒性を阻害する
JP6779866B2 (ja) 2014-06-13 2020-11-04 チルドレンズ メディカル センター コーポレイション ミトコンドリアを単離するための製品および方法
HUE054626T2 (hu) 2014-06-25 2021-09-28 Flamma Spa Eljárás D-arginil-2,6-dimetil-L-tirozil-L-lizil-L-fenilalaninamid elõállítására
WO2016001042A1 (en) 2014-06-30 2016-01-07 Flamma S.P.A. Process for the production of d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
WO2016004093A2 (en) * 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
CN104306954B (zh) * 2014-09-25 2016-08-24 中山大学 Wry三肽在制备治疗阿尔茨海默症药物中的用途
EP3473253A1 (en) 2014-10-29 2019-04-24 University Of Maryland Methods of treating age-related symptoms in mammals and compositions therefor
WO2017015660A1 (en) * 2015-07-23 2017-01-26 Salk Institute For Biological Studies Prevention and treatment of aging and neurodegenerative diseases
US20200308220A1 (en) * 2015-11-30 2020-10-01 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
CN115160402A (zh) 2016-03-11 2022-10-11 隐形生物治疗公司 结晶盐形式
EP3442990A4 (en) 2016-04-11 2019-12-18 Carnot, LLC CHIRAL PEPTIDES
KR20190088520A (ko) 2016-11-30 2019-07-26 주식회사 다이셀 촬상 장치용 렌즈 모듈 및 그의 제조 방법
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
CN115109116A (zh) 2017-08-17 2022-09-27 凯瑞康宁生物工程（武汉）有限公司 活性氧清除剂衍生物的制备及用途
CN111356699B (zh) 2017-09-04 2022-08-23 凯瑞康宁生物工程（武汉）有限公司 活性氧清除剂的制备及用途
JP6958860B2 (ja) * 2017-11-07 2021-11-02 学校法人自治医科大学 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
WO2020131282A1 (en) * 2018-12-18 2020-06-25 Stealth Biotherapeutics Corp. Mitochondria-targeting peptides
EP3962365A4 (en) * 2019-05-02 2023-02-01 Children's Medical Center Corporation THERAPEUTIC AND PROPHYLACTIC USE OF MITOCHONDRIA AND COMBINED MITOCHONDRIAL AGENTS
EP3771467A1 (en) 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm
AU2021340589B2 (en) 2020-09-09 2024-06-13 Social Profit Network Methods and compositions for delivery of biotin to mitochondria

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
ES2085865T3 (es) 1988-06-30 1996-06-16 Astra Ab Analogos de dermorfina, sus metodos de preparacion, composiciones farmaceuticas, y metodos de tratamiento terapeutico que los emplean.
US5602100A (en) 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
US5652122A (en) * 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
ES2117640T3 (es) * 1990-01-17 1998-08-16 Univ California Composicion para mejorar la supervivencia de materiales biologicos.
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
ATE255450T1 (de) * 1995-06-09 2003-12-15 Hisamitsu Pharmaceutical Co Matrix für iontophorese
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
WO1998015274A1 (en) * 1996-10-07 1998-04-16 Eli Lilly And Company Novel compounds useful as neuro-protective agents
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
CA2314267A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
CA2329709A1 (en) * 1998-04-24 1999-11-04 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
GB9905503D0 (en) * 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
US6503713B1 (en) * 1999-10-04 2003-01-07 University Of Medicine And Dentistry Of New Jersey Methods for identifying RNA binding compounds
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
DE60143945D1 (de) * 2000-07-18 2011-03-10 Cornell Res Foundation Inc Medizinische verwendung von agonisten des mu-opioid rezeptors
US6900178B2 (en) * 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
AU2002225767A1 (en) * 2000-11-28 2002-06-11 Guilford Pharmaceuticals Inc. Bisubstituted carbocyclic cyclophilin binding compounds and theirus
US6545097B2 (en) * 2000-12-12 2003-04-08 Scimed Life Systems, Inc. Drug delivery compositions and medical devices containing block copolymer
MXPA03006666A (es) * 2001-01-25 2004-05-31 Guilford Pharm Inc Compuestos de union de ciclofilina carbociclicos trisubstituidos y su uso.
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
EP1381332B1 (en) * 2001-02-16 2009-09-09 Cordis Corporation Balloon catheter stent delivery system with ridges
JP2004526499A (ja) * 2001-03-16 2004-09-02 エスティーエス バイオポリマーズ，インコーポレイティド 複数層ポリマーコーティングを有する薬物添加ステント
WO2002102833A1 (fr) * 2001-06-15 2002-12-27 Senju Pharmaceutical Co., Ltd. Nouveaux derives d'endomorphine
CA2515080C (en) * 2003-02-04 2012-04-10 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
CN100536909C (zh) * 2003-02-04 2009-09-09 科内尔研究基金会 用于防止线粒体通透性改变的方法
DK2604286T3 (en) 2003-05-01 2014-12-08 Cornell Res Foundation Inc Method and carrier complex for delivering molecules to cells
JP2005005762A (ja) * 2003-06-09 2005-01-06 Fujitsu Ltd 送信電力制御方法及び装置
WO2005032481A2 (en) 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
US7550439B2 (en) * 2004-01-23 2009-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
EP1931369B1 (en) 2005-09-16 2016-08-17 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing CD36 expression

Also Published As

Publication number Publication date
US7718620B2 (en) 2010-05-18
US20130244957A1 (en) 2013-09-19
EP3659618A1 (en) 2020-06-03
AU2004209663B2 (en) 2009-01-15
HK1178794A1 (en) 2013-09-19
HK1204999A1 (en) 2015-12-11
JP6166312B2 (ja) 2017-07-19
EP2491943A3 (en) 2013-01-23
CA2515080A1 (en) 2004-08-19
WO2004070054A3 (en) 2005-04-14
JP2006516652A (ja) 2006-07-06
WO2004070054A2 (en) 2004-08-19
US8957030B2 (en) 2015-02-17
US20230293624A1 (en) 2023-09-21
CN104225574B (zh) 2017-01-11
EP1599216B9 (en) 2015-02-11
US20070027087A1 (en) 2007-02-01
DK2865385T3 (en) 2016-12-19
JP2015180693A (ja) 2015-10-15
US20150359838A1 (en) 2015-12-17
SI2656854T1 (sl) 2015-09-30
JP2011026346A (ja) 2011-02-10
US7576061B2 (en) 2009-08-18
DK1599216T3 (da) 2013-12-09
US20200038472A1 (en) 2020-02-06
ES2436011T3 (es) 2013-12-26
JP2013249313A (ja) 2013-12-12
ES2540897T3 (es) 2015-07-14
JP4838114B2 (ja) 2011-12-14
JP6126059B2 (ja) 2017-05-10
DK2656854T3 (en) 2015-07-06
US20100190718A1 (en) 2010-07-29
AU2004209663A1 (en) 2004-08-19
JP2017095519A (ja) 2017-06-01
EP2656854A1 (en) 2013-10-30
EP2865385B1 (en) 2016-11-16
JP2015007127A (ja) 2015-01-15
EP3144009A1 (en) 2017-03-22
HK1190930A1 (en) 2014-07-18
EP2865385A1 (en) 2015-04-29
JP5837542B2 (ja) 2015-12-24
EP1599216B1 (en) 2013-11-06
CY1116575T1 (el) 2017-03-15
CY1114959T1 (el) 2016-12-14
EP2491943A2 (en) 2012-08-29
HK1131995A1 (en) 2010-02-12
US20040248808A1 (en) 2004-12-09
PT2656854E (pt) 2015-09-03
EP2656854B1 (en) 2015-05-20
CA2515080C (en) 2012-04-10
AU2004209663A2 (en) 2004-08-19
JP5775285B2 (ja) 2015-09-09
EP3479838A1 (en) 2019-05-08
JP2019089773A (ja) 2019-06-13
EP3305313A1 (en) 2018-04-11
CN102617706A (zh) 2012-08-01
US20120021970A1 (en) 2012-01-26
EP3842055A1 (en) 2021-06-30
HK1209652A1 (en) 2016-04-08
CN104225574A (zh) 2014-12-24
CN102784383A (zh) 2012-11-21
EP2491943B1 (en) 2018-10-10
US8404646B2 (en) 2013-03-26
ES2605504T3 (es) 2017-03-14
EP1599216A4 (en) 2009-11-11
CN102784383B (zh) 2014-09-17
HUE027110T2 (en) 2016-08-29
PT1599216E (pt) 2013-12-17
EP1599216A2 (en) 2005-11-30

Similar Documents

Publication Publication Date Title
HK1204999A1 (en) Methods for preventing mitochondrial permeability transition
GB2401643B (en) Padlock
HK1088602A1 (en) 2-pyridinecarboxamide derivatives
HK1088326A1 (en) Piperidine-benzenesulfonamide derivatives
HK1089443A1 (en) Imidazol-4-yl-ethynyl-pyridine derivatives
GB0317665D0 (en) Qinazoline derivatives
SI1682493T1 (sl) Amidoacetonitrilni derivati
IL175189A0 (en) N-thiazol-2-yl-benzamide derivatives
GB0326439D0 (en) Methods
AU155985S (en) Beaker
SI1599216T1 (sl) Postopek za preprečevanje mitohondrijskega permeabilnostnega prehoda
PL1706373T3 (pl) Pochodne amidoacetonitrylu
GB0328243D0 (en) Methods
GB0319793D0 (en) Pyridinylmorpholine derivatives
GB0327909D0 (en) Methods
GB0320627D0 (en) Methods
GB0327368D0 (en) Methods
GB0315827D0 (en) Methods
GB0307076D0 (en) Methods
GB0323793D0 (en) Methods
GB0328747D0 (en) Methods
GB0305252D0 (en) Methods
AU2003280821A8 (en) Beauveriolide derivative
TWI341309B (en) Heteroarylcarbamoylbenzene derivatives
GB0330078D0 (en) Methods

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20240202